Medicenna Therapeutics Corp(MDNAF)
$0.13-0.04 (-21.88%)
MDNAF
Medicenna Therapeutics Corp financials statements
$0.13
At close:-0.04 (-21.88%)
Medicenna Therapeutics Corp (MDNAF) Ratios
251 Followers
Medicenna Therapeutics Corp Ratios
MDNAF's free cash flow for Q1 2027 was C$-4.43M. For the 2027 fiscal year, MDNAF's free cash flow was increased by C$0.00 and operating cash flow was C$-4.43M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.52 | 6.35 | 6.66 | 9.57 | 8.92 |
| Quick Ratio | 1.52 | 6.35 | 6.66 | 9.57 | 8.92 |
| Cash Ratio | 1.14 | 5.60 | 5.93 | 8.84 | 7.83 |
| Solvency Ratio | -3.07 | -1.27 | -1.83 | 0.22 | -8.63 |
| Operating Cash Flow Ratio | -3.28 | -3.72 | -5.68 | -3.33 | -9.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 2.35M | C$ 18.88M | C$ 5.13M | C$ 29.43M | C$ 20.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.41 | 1.49 | 3.69 | 1.24 | 1.13 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -327.65 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -323.19 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.26 | 1.90 | 0.91 | 2.06 | 0.91 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 93.44% | 90.60% | 100.00% | -15.40% | 100.31% |
| EBT Per EBIT | 83.10% | 60.24% | 129.51% | 46.43% | 101.24% |
| Return on Assets (ROA) | -217.75% | -41.59% | -133.09% | 4.24% | -96.55% |
| Return on Equity (ROE) | -741.70% | -61.82% | -490.58% | 5.25% | -108.69% |
| Return on Capital Employed (ROCE) | -793.24% | -90.33% | -120.85% | -66.30% | -107.03% |
| Return on Invested Capital (ROIC) | -725.41% | -81.67% | -120.85% | 10.21% | -107.03% |
| Return on Tangible Assets | -218.97% | -41.67% | -133.49% | 4.25% | -96.82% |
| Earnings Yield | -34.58% | -15.71% | -20.20% | 2.72% | -25.28% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.02 | 0.00 | 0.00 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22980.78 | -17924.82 | -151110.00 | -118041.00 | -16060.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 22980.78 | 17924.82 | 151110.00 | 118041.00 | 16060.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.22 | -0.22 | -0.23 | -0.20 | -0.43 |
| Free Cash Flow Per Share | 0.00 | -0.22 | -0.23 | -0.20 | -0.43 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | -499.76 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -1.00 | -499.76 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -150.61 | -98.17 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | 0.00% | -21.99% | -12.90% | -22.22% | -26.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.91 | -6.53 | -4.95 | 36.82 | -3.96 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 21.45 | 3.93 | 24.28 | 1.93 | 4.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | -4.55 | -7.75 | -4.50 | -3.80 |
| Price-to-Operating Cash Flow Ratio | -2.97 | -4.56 | -7.75 | -4.50 | -3.80 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.11 | 0.00 | -0.35 | -0.20 |
| Enterprise Value Multiple | -1.99 | -3.89 | -5.84 | -1.43 | -3.06 |
| Enterprise Value | 47.11M | 50.47M | 109.06M | 23.37M | 69.04M |
| EV to EBITDA | -1.99 | -3.89 | -5.84 | -1.43 | -3.06 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.00 | -3.05 | -6.71 | -1.85 | -2.93 |
| EV to Operating Cash Flow | -2.63 | -3.06 | -6.71 | -1.85 | -2.93 |
| Tangible Book Value Per Share | 0.03 | 0.25 | 0.07 | 0.45 | 0.38 |
| Shareholders’ Equity Per Share | 0.03 | 0.25 | 0.07 | 0.46 | 0.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | 0.09 | 0.00 | 1.15 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.22 | -0.15 | -0.37 | 0.02 | -0.42 |
| Tax Burden | 0.93 | 0.91 | 1.00 | -0.15 | 1.00 |
| Interest Burden | 0.83 | 1.00 | 1.36 | 0.62 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.97 | 1.40 | 0.64 | 1.26 | 1.04 |
Currency in CAD

